Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 885 across all filing types
Latest filing 2026-05-29 Declaration of Voting R…
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 30.04.26
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a notice under French commercial law (article L.233-8 II and AMF rule 223-16) disclosing the number of shares and total voting rights as of 30/04/2026. It is not an earnings release or capital issuance, nor a full financial report. It is a voting rights announcement and matches the ‘Declaration of Voting Results & Voting Rights Announcements’ category (DVA).
2026-05-29 French
ABIVAX: Nombre dactions composant le capital social et nombre total de droits de vote au 30.04.26
Declaration of Voting Results & Voting Rights Announcements Classification · 84% confidence The document is a mandatory regulatory disclosure under French commercial law (L.233-8 II and AMF article 223-16) providing the total number of shares and voting rights as of 30 April 2026. It is not a report of vote results at a meeting, but rather a standardized “voting rights announcement” required semi-annually. This fits the DVA category (“Declaration of Voting Results & Voting Rights Announcements”).
2026-05-29 French
Franchissements de seuils
Major Shareholding Notification Classification · 95% confidence The document is a French AMF filing titled “Déclarations de franchissements de seuils” under article L. 233-7 of the French Code de commerce, detailing JP Morgan’s crossing above and below the 5% voting rights threshold in ABIVAX. This is precisely a notification of significant shareholding changes crossing regulatory thresholds.
2026-05-29 French
Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH
Interim / Quarterly Report Classification · 90% confidence The document is a press release presenting Abivax’s first-quarter 2026 financial performance, including substantive IFRS tables (cash flow, P&L, balance sheet) and detailed operating metrics. It contains actual financial statements for the quarter (not merely high-level bullet points), thus meeting the definition of an Interim/Quarterly Report rather than a simple Earnings Release or Report Publication Announcement. Q1 2026
2026-05-22 French
Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
Earnings Release Classification · 98% confidence The document is a press release announcing Abivax’s first quarter 2026 financial results, including key highlights (cash position, expense breakdowns) and selected IFRS financial tables. It is styled as an earnings announcement rather than a full annual or interim report filed in regulatory format. There is no indication that this is the full interim report itself, but rather an earnings release summarizing quarterly results. Therefore, it is classified as an Earnings Release (ER). Q1 2026
2026-05-22 English
Etats financiers consolidés condensés intermédiaires (non audités) au 31 mars 2026
Interim / Quarterly Report Classification · 95% confidence The document is a full condensed interim consolidated financial report (non-audited) covering the quarter ended 31 March 2026, prepared under IFRS, and includes balance sheets, income statements, cash flows, risk factors, management discussion, and other substantive financial data. It is not merely an announcement or presentation but the actual interim financial statements. Therefore, it is classified as an Interim / Quarterly Report (IR). Q1 2026
2026-05-22 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.